WAP
BPMC

Wealthcare Advisory Partners’s Blueprint Medicines BPMC Stock Holding History

Wealthcare Advisory Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed – – 1231
2018
Q2 		$0 Hold
1
– – ﹤0.01% 1234
2018
Q1 		$0 Buy
+1
New +$86 ﹤0.01% 1089

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Wealthcare Advisory Partners's BPMC Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of Blueprint Medicines (BPMC) in Q3 2018, closing a stake of 1 share.

Wealthcare Advisory Partners first reported a position in BPMC in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 188 funds tracked by Wall St. Rank hold BPMC as of Q3 2018.

  • Wealthcare Advisory Partners reported no remaining Blueprint Medicines position as of Q3 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 1 Blueprint Medicines share in Q3 2018.
  • Wealthcare Advisory Partners first reported a position in Blueprint Medicines in Q1 2018 and held it in 2 quarters.
  • Wealthcare Advisory Partners's Blueprint Medicines position peaked at $0 in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.